Endocrine Regulations (Jul 2021)

Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis

  • Duarte Diana Borges,
  • Silva Ana Martins da,
  • Freitas Claudia,
  • Cardoso Helena

DOI
https://doi.org/10.2478/enr-2021-0018
Journal volume & issue
Vol. 55, no. 3
pp. 169 – 173

Abstract

Read online

Objectives. Immune reconstitution therapies (IRT), which include antibody-based cell-depleting therapies targeting CD52+ (alemtuzumab) or CD20+ (rituximab, ocrelizumab) leukocytes, are approved for the treatment of multiple sclerosis. Thyroid autoimmunity is a common adverse effect of alemtuzumab treatment, Graves’ disease (GD) being the most prevalent manifestation. To date, thyroid autoimmunity events have not been reported with CD20-targeting monoclonal antibodies.

Keywords